Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader (SERD), in patients with ...
Ro launches access to Eli Lilly's single-dose vials of GLP-1 Zepbound. Eli Lilly (LLY) concluded the recent trading session at $796.03, signifying a -0.44% move from its prior day's close.
Eva Altamirano (South Plainfield) won in sudden victory overtime against Liliana Zaku-Ramos (Newton) in a 126-pound semifinal bout at the 2024 NJSIAA State Wrestling Championships, Friday, March 1, ...
After blind review by community volunteers of the initial Lilly Endowment Community Scholarship applications, nine finalists were selected — six young women and three young men. This year’s finalists ...